Ipsen outlines $461m for ex-US rights to Day One’s glioma therapy
Ipsen will pay $111m in cash and equity upfront to gain the global rights, excluding the US, to Day One’s paediatric glioma therapy, Ojemda.
Ipsen will pay $111m in cash and equity upfront to gain the global rights, excluding the US, to Day One’s paediatric glioma therapy, Ojemda.
What's Your Reaction?
